The use of green tea in the treatment of symptomatic uterine fibroids
Keywords:
Green Tea, Symptomatic Uterine FibroidsAbstract
Background: Green tea is a natural product, commonly used by women for multiple purposes. Epigallocatechin gallate (EGCG), the major catechin in green tea, exhibits several useful biological effects, including anti-inflammatory, antiproliferative, and antioxidant effects. A study conducted by the US Department of Agriculture reported that green tea has potent anticancer effects against a wide range of human cancer cells. Green tea’s polyphenols are considered responsible for these positive effects, and most notably EGCG has been shown to inhibit key pathways of tumor growth. Objective: Aim of the work was to study the effects of epigallocatechin gallate (EGCG), an extract of green tea on human leiomyoma and quality of life in women with symptomatic uterine fibroids. Patients and methods: A Prospective, sealed envelopes, randomized control trial was conducted including 75 reproductive-age women with symptomatic uterine fibroids (UF) were recruited for this study. All subjects had at least one fibroid lesion ≥ 2 cm³, as confirmed by transvaginal ultrasonography. The subjects had been randomized by SNOSE (Sequentially Numbered Opaque Sealed Envelopes); to oral daily treatment with either 900 mg of green tea extract or only symptomatic treatment for 4 months. The duration of study was about 3 years.
Downloads
References
Sharma D, Kosankar KV. (2018): Green Tea in Green World an updated review. Pharma Tutor., 6(3): 9-16.
Roshdy E, Rajaratnam V, Maitra S, Sabry M, Allah AS, Al-Hendy A. (2013): Treatment of symptomatic uterine fibroids with green tea extract: a pilot randomized controlled clinical study. Int J Womens Health, 5: 477-486.
Musial C, Kuban-Jankowska A, Gorska-Ponikowska M. (2020): Beneficial Properties of Green Tea Catechins. International Journal of Molecular Sciences, 21(5):1744.
Aggarwal BB, Shishodia S. (2006): Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol., 71(10):1397–421.
Swarnalatha G, Surendra Nath B, Laxmana Naik N, Heartwin Amaladhas P, Magdaline Eljeeva Emerald F. (2021): Therapeutic Potential of Green Tea Catechins - A Magical Herb. Int J Curr Microbiol App Sci., 10(02): 3560-3571.
Caltagirone S, Rossi C, Poggi A, Ranelletti FO, Natali PG, Brunetti M, Aiello FB, Piantelli M. (2000): Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential. Int J Cancer, 87: 595–600.
Suganuma M, Okabe S, Sueoka N, Sueoka E, Matsuyama S, Imai K, Nakachi K, Fujiki H. (1999): Green tea and cancer chemoprevention. Mutat Res., 428: 339–344.
Stewart EA. (2001): Uterine fibroids. Lancet, 357(9252): 293–8.
Stewart EA, Cookson CL, Gandolfo RA, Schulze-Rath R. (2017): Epidemiology of uterine fibroids: A systematic review. BJOG, 124(10):1501-1512.
Parker WH. (2007): Etiology, symptomatology, and diagnosis of uterine myomas. Fertil Steril., 87(4): 725–736.
Salama SA, Kamel M, Christman G, Wang HQ, Fouad HM, Al-Hendy A. (2007): Gene therapy of uterine leiomyoma: adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir treatment inhibits growth of human and rat leiomyoma cells in vitro and in a nude mouse model. Gynecol Obstet Invest., 63(2):61–70.
Deeba N, Syed NK, Farrukh A, Hasan M. (2007): Chemoprevention of Prostate Cancer through Dietary Agents: Progress and Promise. Cancer Epidemiology Biomarkers & Prevention, 16: 2193–2203.
McLucas B. (2008): Diagnosis, imaging and anatomical classification of uterine fibroids. Best Pract Res Clin Obstet Gynaecol., 22: 627–642.
Van den bosch T, Dueholm M, Leone FPG, Valentin L. (2015): Terms, definitions and measurements to describe sonographic features of myometrium and uterine masses: a consensus opinion from the Morphological Uterus Sonographic Assessment (MUSA) group Ultrasound Obstet Gynecol., 46: 284–298.
Faul F, Erdfelder E, Lang AG, Buchner A. (2007): G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behavior Research Methods, 39: 175-191.
Miriello D, Galanti F, Cignini P, Antonaci D, Schiavi MC, Rago R. (2021): Uterine fibroids treatment: do we have new valid alternative? Experiencing the combination of vitamin D plus epigallocatechin gallate in childbearing age affected women. Eur Rev Med Pharmacol Sci., 25(7):2843-2851.
Mavrelos D, Ben-Nagi J, Holland T, Hoo W, Naftalin J, Jurkovic D. (2010): The natural history of fibroids. Ultrasound Obstet Gynecol., 35(2):238-42.
Bukulmez O, Doody KJ. (2006): Clinical features of myomas. Obstet Gynecol Clin North Am., 33(1):69-84.
Grandi G, Del Savio MC, Melotti C, Feliciello L, Facchinetti F. (2021): Vitamin D and green tea extracts for the treatment of uterine fibroids in late reproductive life: a pilot, prospective, daily-diary based study. Gynecol Endocrinol., 16: 1-5.
Donnez J, Donnez O, Matule D, Ahrendt HJ, Hudecek R, Zatik J, Kasilovskiene Z, Dumitrascu MC, Fernandez H, Barlow DH. (2016): Long–term medical management of uterine fibroids with ulipristal acetate. Fertil Steril., 105:165–173.
Friedman AJ, Hoffman DI, Comite F, Browneller RW, Miller JD. (1991): Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, multicenter study. The Leuprolide Study Group. Obstet Gynecol., 77(5):720-5.
Carbonell Esteve JL, Riverón AM, Cano M, Ortiz AI, Valle A, Texidó CS, Tomasi G. (2012): Mifepristone 2.5 mg versus 5 mg daily in the treatment of leiomyoma before surgery. Int J Womens Health, 4: 75-84.
Khan MK, Zill Huma, Dangles O. (2014): A comprehensive review on flavones, the major citrus polyphenols. J Food Comp Anal., 33(1):85–104.
Zhang D, Rajaratnam V, Al-Hendy O, Halder S, Al-Hendy A. (2014): Green tea extract inhibition of human leiomyoma cell proliferation is mediated via catechol-O-methyltransferase. Gynecologic and Obstetric Investigation, 78(2): 109-118.
Zhang D, Al-Hendy M, Richard-Davis G, Montgomery-Rice V, Sharan C, Rajaratnam V, Khurana A, Al-Hendy A. (2010): Green tea extract inhibits proliferation of uterine leiomyoma cells in vitro and in nude mice. Am J Obstet Gynecol., 202(3):289-97.
Pérez-López FR. (2015): Ulipristal acetate in the management of symptomatic uterine fibroids: facts and pending issues. Climacteric, 18(2):177-81.
Millo N, Boroditsky R, Lyons EA. (2010): Fibroids treated with uterine artery embolization: do imaging findings correlate with patient outcomes? J Obstet Gynaecol Can., 32(5):460-466.
Goodwin SC, Spies JB, Worthington-Kirsch R, Peterson E, Pron G, Li S, Myers ER, Committee FT, Investigators CS. (2008): Uterine Artery Embolization for Treatment of Leiomyomata: Long-Term Outcomes From the FIBROID Registry. Obstetrics & Gynecology, 111: 22-33.
Ciarmela P, Delli Carpini G, Greco S, Zannotti A, Montik N, Giannella L, Giuliani L, Grelloni C, Panfoli F, Paolucci M, Pierucci G, Ragno F, Pellegrino P, Petraglia F, Ciavattini A. (2021): Uterine fibroid vascularization: from morphological evidence to clinical implications. Reprod Biomed Online, 20: 1472-6483.
Idowu BM, Ibitoye BO, Adetiloye VA. (2017): Uterine Artery Doppler Velocimetry of Uterine Leiomyomas in Nigerian Women. Rev Bras Ginecol Obstet., 39(9):464-470.
Jinhe R. (2017): Color Doppler Ultrasound in Uterine Arterial Embolization. Open Med (Wars), 12: 489-493.
Naguib NN, Nour‐Eldin NE, Serag‐Eldin F, Mazloum YZ, Agameya AF, Abou‐Seif S, Etaby AN, Lehnert T, Gruber‐Rouh T, Zangos S, Ackermann H. (2012): Role of uterine artery Doppler in the management of uterine leiomyoma by arterial embolization. Ultrasound in Obstetrics & Gynecology, 40(4): 452-458.
Gupta JK, Sinha A, Lumsden MA, Hickey M. (2014): Uterine artery embolization for symptomatic uterine fibroids. Cochrane Database Syst Rev., 12: CD005073.
Kanelopoulos N, Dendrinos S, Oikonomou A, Panagopoulos P, Markussis V. (2003): Doppler-ultrasound as a predictor of uterine fibroid response to GnRH therapy. Int J Gynaecol Obstet., 82(1):41-7.
Chen IJ, Liu CY, Chiu JP, Hsu CH. (2016): Therapeutic effect of high-dose green tea extract on weight reduction: A randomized, double-blind, placebo-controlled clinical trial. Clin Nutr., 35(3):592-9.
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
